Shrisha et al | DOI: 10.65188/nurexus.1016
Nurexus | Journal of MedVerse Research and Practice | Volume 3 | Issue – 03 | March 2025
Page 13
Journal of MedVerse Research & Practice
nurexus.com
Managing Short Bowel Syndrome in Neonates and Young Infants: A
Clinical Overview
Dr. Shrisha
1
, Dr. Surya
2
Postgraduate, Assistant Professor
Department of Pediatrics, SRM Medical College Hospital, Trichy
Email: Shrisha789@gmail.com
Submission Date: 24.02.2025
Accepted Date: 22.03.2025
Published Date: 31.03.2025
DOI: 10.65188/nurexus.1016
Copyright © 2025. The author(s). Published by Journal of MedVerse Research and Practice. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
Abstract
Short bowel syndrome (SBS) is a significant condition in neonates and infants, resulting from extensive bowel
resection due to congenital or acquired causes. This disorder leads to malabsorption, posing challenges in nutrient
absorption and overall growth. Advances in neonatal care and surgical techniques have improved survival rates, but
long-term management remains complex. This review explores the etiologies, clinical manifestations, diagnostic
approaches, and treatment strategies for SBS in early life. Current therapeutic approaches include parenteral
nutrition, enteral feeding advancements, surgical interventions, and emerging regenerative therapies. A
multidisciplinary approach is crucial for optimizing outcomes, enhancing quality of life, and reducing dependency on
parenteral nutrition. Further research is necessary to develop innovative treatments that support intestinal adaptation
and improve long-term prognosis.
Keywords: Short Bowel Syndrome, Neonates, Infants, Malabsorption, Intestinal Adaptation, Parenteral Nutrition
Introduction
Short bowel syndrome (SBS) is a rare yet serious condition affecting neonates and infants, primarily
resulting from congenital anomalies or surgical resection due to necrotizing enterocolitis, intestinal atresia,
or midgut volvulus [1]. This disorder is characterized by significant malabsorption, leading to nutritional
deficiencies, dehydration, and failure to thrive [2]. The severity of SBS depends on the remaining bowel
length and its ability to adapt over time [3].
Advancements in neonatal intensive care and surgical interventions have significantly improved the
survival of infants with SBS. However, managing this condition remains challenging due to the long-term
dependence on parenteral nutrition (PN), which carries risks of liver dysfunction, infections, and metabolic
complications [4]. The goal of SBS management is to promote intestinal adaptation, enabling a gradual
transition to enteral nutrition while minimizing complications [5].
Several therapeutic strategies have been explored to enhance intestinal adaptation, including optimized
nutritional support, pharmacological agents, and surgical approaches such as bowel lengthening procedures
[6]. Emerging regenerative therapies, including tissue engineering and stem cell applications, hold promise
for improving outcomes in affected infants [7]. This review aims to provide a comprehensive overview of
the pathophysiology, diagnostic approaches, and evolving treatment modalities for SBS in neonates and
Shrisha et al | DOI: 10.65188/nurexus.1016
Nurexus | Journal of MedVerse Research and Practice | Volume 3 | Issue – 03 | March 2025
Page 14
early infancy. Understanding the latest advancements in management strategies is crucial for optimizing
care and improving long-term prognosis [8].
Definition of Short Bowel Syndrome
Short bowel syndrome (SBS) is a disorder characterized by the loss or malfunction of a significant portion
of the small intestine, resulting in severe malabsorption and the inability to sustain adequate nutrition
through oral intake alone [9]. The severity of SBS is influenced by multiple factors, including the length of
the residual bowel, the specific intestinal segments remaining, and the body's capacity for intestinal
adaptation [10]. Patients with SBS often require intensive medical support, particularly specialized
nutritional strategies, to compensate for reduced absorptive capacity and to prevent malnutrition-related
complications [11].
Cause
The underlying causes of SBS in neonates and infants can be classified into congenital and acquired
conditions. Congenital causes include intestinal atresia, gastroschisis, and congenital short bowel
syndrome, which result in an underdeveloped or abnormally short intestine at birth [12]. Acquired causes,
on the other hand, involve the necessity of extensive bowel resection due to severe conditions such as
necrotizing enterocolitis, midgut volvulus, intestinal ischemia, and traumatic bowel injury [13]. The
etiology of SBS plays a pivotal role in determining prognosis, influencing the potential for intestinal
adaptation and long-term clinical outcomes [14].
Pathophysiology
SBS disrupts normal gastrointestinal function by drastically reducing the intestinal surface area available
for digestion and nutrient absorption [15]. The degree of malabsorption depends on the extent and location
of the remaining intestine, as different intestinal segments perform distinct roles in nutrient absorption. The
duodenum and jejunum are primarily responsible for absorbing carbohydrates, proteins, and fats, while the
ileum is essential for vitamin B12 absorption and bile acid reuptake [16].
Following intestinal resection, the remaining bowel initiates a compensatory adaptive response aimed at
increasing its absorptive efficiency. This adaptive process is marked by structural and functional changes,
including villous hyperplasia, increased crypt cell proliferation, and the upregulation of nutrient transporter
proteins, all of which contribute to improved absorption [17]. Several factors modulate the extent of
intestinal adaptation, including the presence of the ileocecal valve, the remaining length of the small
intestine, and the role of the colon in enhancing digestion and fluid retention [18].
Predictors of Enteral Autonomy
Enteral autonomy is defined as the ability of an individual with SBS to maintain adequate nutritional intake
through enteral feeding alone, without the need for long-term parenteral nutrition [19]. Several key
determinants influence the likelihood of achieving enteral independence, including the residual bowel
length, the functionality of the ileocecal valve, and the extent of colonic involvement in nutrient and fluid
absorption [20].
Early initiation and gradual progression of enteral feeding are crucial for stimulating intestinal adaptation,
improving absorptive efficiency, and facilitating enteral autonomy [21]. Emerging pharmacological
therapies, such as glucagon-like peptide-2 (GLP-2) analogs, have demonstrated efficacy in enhancing
intestinal adaptation by promoting mucosal growth and increasing nutrient absorption capacity [22].
Moreover, a comprehensive multidisciplinary approach incorporating optimized nutrition plans, surgical
techniques, and novel therapeutic interventions has significantly improved the likelihood of weaning
patients from parenteral nutrition, thereby reducing associated complications and enhancing overall quality
Shrisha et al | DOI: 10.65188/nurexus.1016
Nurexus | Journal of MedVerse Research and Practice | Volume 3 | Issue – 03 | March 2025
Page 15
of life [23].
Complications
Short bowel syndrome (SBS) is associated with a wide range of complications that significantly impact
patient outcomes and quality of life. These complications arise due to severe malabsorption, intestinal
dysmotility, and prolonged dependence on parenteral nutrition (PN) [24]. One of the most common
complications is intestinal failure-associated liver disease (IFALD), which results from prolonged PN use,
leading to cholestasis, hepatic fibrosis, and potential liver failure [25]. Catheter-related bloodstream
infections (CRBSIs) pose another serious risk, as the long-term requirement for central venous catheters
increases susceptibility to infections, sepsis, and thrombotic complications [26].
Nutritional deficiencies are another major concern in SBS patients, as impaired absorption leads to deficits
in essential macronutrients and micronutrients, including fat-soluble vitamins (A, D, E, and K), iron, zinc,
and calcium, which can cause growth failure, osteoporosis, and immune dysfunction [27]. Additionally,
fluid and electrolyte imbalances, particularly sodium and potassium losses, contribute to chronic
dehydration and metabolic derangements, necessitating careful monitoring and supplementation [28].
Patients with SBS may also experience small intestinal bacterial overgrowth (SIBO), which exacerbates
malabsorption by disrupting gut microbiota and increasing the risk of diarrhea, bloating, and malnutrition
[29]. Furthermore, those who undergo bowel lengthening procedures are at risk of developing anastomotic
strictures, intestinal obstructions, and recurrent episodes of bowel dilatation [30].
Management
The management of SBS requires a multidisciplinary approach aimed at optimizing intestinal adaptation,
minimizing complications, and improving long-term nutritional independence [31]. The cornerstone of
treatment is nutritional support, which initially relies on PN to meet caloric and fluid requirements while
gradually transitioning to enteral feeding to stimulate intestinal adaptation and promote functional recovery
[32].
Enteral nutrition plays a critical role in SBS management by enhancing gut motility, promoting mucosal
growth, and reducing dependency on PN. The introduction of trophic feeds at an early stage, even in
minimal amounts, has been shown to facilitate intestinal adaptation and improve long-term outcomes [33].
Specialized diets, including elemental and semi-elemental formulas, are often used to enhance nutrient
absorption in patients with compromised digestive capacity [34].
Pharmacological interventions have emerged as key components in SBS management, particularly
glucagon-like peptide-2 (GLP-2) analogs such as teduglutide, which have demonstrated effectiveness in
promoting intestinal growth, increasing nutrient absorption, and reducing the need for PN [35]. Other
supportive medications include anti-motility agents like loperamide and proton pump inhibitors to manage
diarrhea and acid-related complications, respectively [36].
Surgical approaches are considered in cases where conservative management fails to achieve enteral
autonomy. Intestinal lengthening procedures, including the Bianchi and serial transverse enteroplasty
(STEP) techniques, aim to increase bowel surface area and improve absorptive function [37]. In severe
cases, intestinal transplantation may be considered for patients who develop irreversible complications
from PN, such as life-threatening liver disease or recurrent sepsis [38].
Emerging therapies in regenerative medicine, including tissue engineering and stem cell therapy, hold
promise for revolutionizing SBS treatment by enhancing mucosal regeneration and restoring functional
Shrisha et al | DOI: 10.65188/nurexus.1016
Nurexus | Journal of MedVerse Research and Practice | Volume 3 | Issue – 03 | March 2025
Page 16
intestinal tissue [39]. Advances in microbiome research are also paving the way for novel therapeutic
strategies, such as fecal microbiota transplantation, to modulate gut flora and improve nutrient absorption
[40]. Ultimately, a tailored, patient-centered approach integrating nutritional, pharmacological, and surgical
Strategies are crucial for optimizing SBS outcomes and improving survival rates in neonates and infants
[41].
Pharmacological Approaches in SBS
Pharmacological interventions have emerged as key components in SBS management, particularly
glucagon-like peptide-2 (GLP-2) analogs such as teduglutide, which have demonstrated effectiveness in
promoting intestinal growth, increasing nutrient absorption, and reducing the need for PN [35]. Other
supportive medications include anti-motility agents like loperamide and proton pump inhibitors to manage
diarrhea and acid-related complications, respectively [36].
Prevention and Management of Central Line-Associated Bloodstream Infections (CLABSI):
Given the dependence on long-term PN, SBS patients are highly susceptible to CLABSI, which can lead to
sepsis and life-threatening complications. Preventative strategies include strict aseptic techniques during
catheter insertion and maintenance, regular monitoring for early signs of infection, ethanol lock therapy,
and antibiotic prophylaxis when necessary [37]. The proper education of caregivers and healthcare
providers plays a critical role in reducing infection rates and improving patient outcomes [38].
Surgical Considerations in SBS Treatment
Surgical interventions are considered for patients with SBS when conservative measures fail to achieve
enteral autonomy. Intestinal lengthening procedures, such as the Bianchi and serial transverse enteroplasty
(STEP) techniques, increase the functional surface area of the small intestine, enhancing nutrient absorption
[39]. For patients with irreversible complications related to PN, intestinal transplantation remains a viable
option, offering improved survival and quality of life [40].
Mucous Fistula Refeeding (MFR) and Stoma Reversal
MFR has emerged as a beneficial technique in neonates and infants with SBS, allowing the use of proximal
enteric secretions to enhance intestinal adaptation and promote mucosal growth. This method facilitates the
reintroduction of gut nutrients, ultimately aiding in the transition towards full enteral feeding [41]. Stoma
reversal, performed when the residual bowel has achieved sufficient adaptation, further supports the
restoration of intestinal continuity, improving nutrient absorption and reducing dependence on PN [42].
Prognosis and Long-Term Outcomes:
The prognosis of SBS largely depends on the residual bowel length, underlying etiology, and the success of
intestinal adaptation. Advances in medical and surgical management have significantly improved survival
rates, with many patients achieving partial or complete enteral autonomy over time. Long-term follow-up is
essential to monitor for complications such as nutritional deficiencies, liver dysfunction, and growth
impairment [43]. Emerging therapies, including regenerative medicine and gut microbiome modulation,
hold promise for further improving outcomes in affected individuals [44,45].
Conclusion
SBS remains a complex and challenging condition requiring a comprehensive, patient-centered approach.
Advances in nutritional support, pharmacological interventions, surgical techniques, and emerging
therapies have significantly enhanced the management and prognosis of SBS patients. Continued research
and multidisciplinary collaboration are crucial in optimizing long-term outcomes and improving the quality
of life for individuals affected by this disorder
Shrisha et al | DOI: 10.65188/nurexus.1016
Nurexus | Journal of MedVerse Research and Practice | Volume 3 | Issue – 03 | March 2025
Page 17
Conflict of Interest: Nil
Reference
1. Fallon EM, Mitchell PD, Nehra D, Potemkin AK, O’Loughlin AA, Gura KM, et al. Neonates with short
bowel syndrome: An optimistic future for parenteral nutrition independence. JAMA Surg. 2014; 149:663–70.
Available from: https://doi.org/10.1001/jamasurg.2013.4332
2. Han SM, Knell J, Henry O, Hong CR, Han GY, Staffa SJ, et al. Long-term outcomes and disease burden of
neonatal on set short bowel syndrome. J Pediatr Surg. 2020; 55:164-8. Available
https://doi.org/10.1016/j.jpedsurg.2019.09.071. from:
3. Modi BP, Langer M, Ching YA, Valim C, Waterford SD, Igle sias J, et al. Improved survival in a
multidisciplinary short bowel syndrome program. J Pediatr Surg. 2008; 43:20e4. 4. 5.
4. Modi BP, Galloway DP, Gura K, Nucci A, Plogsted S, Tucker A, et al. ASPEN definitions in pediatric
intestinal failure. JPEN J Parenter Enteral Nutr. 2022; 46:42-59. Available from:
https://doi.org/10.1002/jpen.2232. Epub 2021 Sep 15. PMID: 34287974.
5. Merritt RJ, Cohran V, Raphael BP, Sentongo T, Volpert D, Warner BW, et al. Nutrition Committee of the
North Ameri can Society for Pediatric Gastroenterology, Hepatology and Nutrition. Intestinal rehabilitation
programs in the man agement of pediatric intestinal failure and short bowel syn drome. J Pediatr
Gastroenterol Nutr. 2017; 65:588-96.
6. Struijs MC, Diamond IR, de Silva N, Wales PW. Establish ing norms for intestinal length in children. J
Pediatr Surg. 2009; 44:933-8. Available https://doi.org/10.1016/j.jpedsurg.2009.01.031. 7. from:
7. O'Keefe SJ, Buchman AL, Fishbein TM, Jeejeebhoy KN, Jeppesen PB, Shaffer J. Short bowel syndrome and
intesti nal failure: consensus definitions and overview. Clin Gas troenterol Hepatol. 2006; 4:6-10. Available
from: https://doi.org/10.1016/j.cgh.2005.10.002. 8.
8. Batra A, Keys SC, Johnson MJ, Wheeler RA, Beattie RM. Epidemiology, management, and outcome of
ultrashort bowel syndrome in infancy. Arch Dis Childhood-Fetal Neo natal Edition. 2017; 102:F551-6.
9. Duro D, Kamin D, Duggan C. Overview of pediatric short bowel syndrome. J Pediatr Gastroenterol Nutr.
2008; 47:S33-6. Available from: https://doi.org/10.1097/MPG.0b013e3181819007.
10. Wales PW, de Silva N, Kim J, Lecce L, To T, Moore A. Neo natal short bowel syndrome: population-based
estimates of incidence and mortality rates. J Pediatr Surg. 2004; 39:690-5.
11. Khan FA, Squires RH, Litman HJ, Balint J, Carter BA, Fisher JG, et al. Pediatric Intestinal Failure
Consortium Predictors of enteral autonomy in children with intestinal failure: A multicenter cohort study. J
Pediatr. 2015; 167:29-34. Available from: https://doi.org/10.1016/j.jpeds.2015.03.040.
12. Peters FB, Bone JN, Van Oerle R, Albersheim S, Casey L, Piper H. The Importance of the ileocecal valve
and colon in achieving intestinal independence in infants with short bowel syndrome. J Pediatr Surg. 2022;
57:117-121. Availa ble from: https://doi.org/10.1016/j.jpedsurg.2021.09.028.
13. Engelstad HJ, Danko ME. Short bowel syndrome in an infant. Neoreviews. 2020; 21:e370-e382. Available
from: https://doi.org/10.1542/neo.21-6-e370.
14. Bailly-Botuha C, Colomb V, Thioulouse E, Berthe MC, Gar cette K, Dubern B, et al. Plasma citrulline
concentration re flects enterocyte mass in children with short bowel syn drome. Pediatr Res. 2009; 65:559-
63.
15. Proli F, Faragalli A, Talbotec C, Bucci A, Zemrani B, Char dot C, et al. Variation of plasma citrulline as a
predictive factor for weaning off long-term parenteral nutrition in children with neonatal short bowel
syndrome. Clin Nutr. 2021; 40:4941-4947. Available from: https://doi.org/10.1016/j.clnu.2021.07.017.
16. Doldi SB. Intestinal adaptation following jejunoileal bypass. Clin Nutr. 1991; 10:138-45.
17. Warner BW. The pathogenesis of resection-associated intes tinal adaptation. Cellular Molecul Gastroenterol
Hepatol. 2016; 2:429-38.
18. Tappenden KA. Intestinal adaptation following resection. JPEN J Parenter Enteral Nutr. 2014; 38:23S-31S.
Available from: https://doi.org/10.1177/0148607114525210.
19. Piper HG, de Silva NT, Amaral JG, Avitzur Y, Wales PW. Peripherally inserted central catheters for long-
term paren teral nutrition in infants with intestinal failure. J Pediatr Gastroenterol Nutr. 2013; 56:578-81.
Available from: https://doi.org/10.1097/MPG.0b013e3182801e7b.
Shrisha et al | DOI: 10.65188/nurexus.1016
Nurexus | Journal of MedVerse Research and Practice | Volume 3 | Issue – 03 | March 2025
Page 18
20. Khalaf RT, Sokol RJ. New insights into intestinal failure associated liver disease in children. Hepatol. 2020;
71:1486-98. Available from: https://doi.org/10.1002/hep.31152.
21. Gutierrez IM, Kang KH, Calvert CE, Johnson VM, Zurakow ski D, Kamin D, et al. Risk factors for small
bowel bacterial overgrowth and diagnostic yield of duodenal aspirates in children with intestinal failure: a
retrospective review. J Pe diatr Surg. 2012; 47:1150-4. Available from:
https://doi.org/10.1016/j.jpedsurg.2012.03.019.
22. Grace E, Shaw C, Whelan K, Andreyev HJ. Small intestinal bacterial overgrowth--prevalence, clinical
features, current and developing diagnostic tests, and treatment. Aliment Pharmacol Ther. 2013; 38:674-88.
23. Puwanant M, Mo-Suwan L, Patrapinyokul S. Recurrent D lactic acidosis in a child with short bowel
syndrome. Asia Pac J Clin Nutr. 2005; 14:195-8.
24. Feng H, Zhang T, Yan W, Lu L, Tao Y, Cai W, et al. Micro nutrient deficiencies in pediatric short bowel
syndrome: a 10-year review from an intestinal rehabilitation center in China. Pediatr Surg Int. 2020;
36:1481-7. Available from: https://doi.org/10.1007/s00383-020-04764-3.
25. Duro D, Jaksic T, Duggan C. Multiple micronutrient defi ciencies in a child with short bowel syndrome and
normal somatic growth. J Pediatr Gastroenterol Nutr. 2008; 46:461-4.
26. Crealey M, Walsh M, Awadalla S, Murphy JF. Managing newborn ileostomies. Ir Med J. 2014; 107:146-8.
27. Butterworth SA, Lalari V, Dheensaw K. Evaluation of sodi um deficit in infants undergoing intestinal
surgery. J Pedi atr Surg. 2014; 49:736–40.
28. Norsa L, Nicastro E, Di Giorgio A, Lacaille F, D'Antiga L. Prevention and treatment of intestinal failure-
associated liver disease in children. Nutrients. 2018; 10:664. Available from:
https://doi.org/10.3390/nu10060664.
29. Raphael BP, Mitchell PD, Gura KM, Potemkin AK, Squires RH, Puder M, et al. Growth in infants and
children with in testinal failure-associated liver disease treated with intra venous fish oil. J Pediatr
Gastroenterol Nutr. 2020; 70:261 8. Available from: https://doi.org/10.1097/MPG.0000000000002551.
30. Lacaille F, Gupte G, Colomb V, D'Antiga L, Hartman C, Hojsak I, et al. ESPGHAN Working Group of
Intestinal Fail ure and Intestinal Transplantation. Intestinal failure associated liver disease: a position paper
of the ESPGHAN Working Group of Intestinal Failure and Intestinal Trans plantation. J Pediatr
Gastroenterol Nutr. 2015; 60:272-83. Available from: https://doi.org/10.1097/MPG.0000000000000586.
31. Nghiem-Rao TH, Cassidy LD, Polzin EM, Calkins CM, Arca MJ, Goday PS. Risks and benefits of
prophylactic cyclic parenteral nutrition in surgical neonates. Nutr Clin Pract. 2013; 28:745-52. Available
from: https://doi.org/10.1177/0884533613502813.
32. Olieman JF, Penning C, Ijsselstijn H, Escher JC, Joosten KF, Hulst JM, et al. Enteral nutrition in children
with short-bowel syndrome: current evidence and recommenda tions for the clinician. J Am Diet Assoc.
2010; 110:420-6. Available from: https://doi.org/10.1016/j.jada.2009.12.001.
33. Ekingen G, Ceran C, Guvenc BH, Tuzlaci A, Kahraman H. Early enteral feeding in newborn surgical
patients. Nutri tion. 2005; 21:142-6. Available from: https://doi.org/10.1016/j.nut.2004.10.003.
34. Teresa C, Valerio N, Laura S, Salvatore C, Francesca L, Alessandra L, et al. Enteral nutrition in pediatric
intestinal failure: does initial feeding impact on intestinal adapta tion?, Expert Rev Gastroenterol Hepatol.
2017; 11:741-8, Available from: https://doi.org/10.1080/17474124.2017.1335196.
35. Bhatia J, Gates A, Parish A. Medical management of short gut syndrome. J Perinatol. 2010; 30:S2-5.
36. Diamanti A, Fiocchi AG, Capriati T, Panetta F, Pucci N, Bellucci F, et al. Cow's milk allergy and neonatal
short bowel syndrome: comorbidity or true association? Eur J Clin Nutr. 2015; 69:102-6. Available from:
https://doi.org/10.1038/ejcn.2014.156.
37. Oly F, Dray X, Corcos O, Barbot L, Kapel N, Messing B. Tube feeding improves intestinal absorption in
short bowel syndrome patients. Gastroenterol. 2009; 136:824-31. Available from:
https://doi.org/10.1053/j.gastro.2008.10.084.
38. Kumpf VJ. Pharmacologic management of diarrhea in pa tients with short bowel syndrome. JPEN J Parenter
Enteral Nutr. 2014; 38:38S-44S. Available from: https://doi.org/10.1177/0148607113520618.
39. Raphael BP, Nurko S, Jiang H, Hart K, Kamin DS, Jaksic T, et al. Cisapride improves enteral tolerance in
pediatric short-bowel syndrome with dysmotility. J Pediatr Gastroen terol Nutr. 2011; 52:590-4. Available
from: https://doi.org/10.1097/MPG.0b013e3181fe2d7a.
Shrisha et al | DOI: 10.65188/nurexus.1016
Nurexus | Journal of MedVerse Research and Practice | Volume 3 | Issue – 03 | March 2025
Page 19
40. Kouti V, Papazoglou L, Flaskos J, Angelopoulou K, Karkavelas G, Rallis T. Ursodeoxycholic acid promotes
in testinal adaptation in a cat model of short bowel syndrome. Fundam Clin Pharmacol. 2011; 25:734-42.
Available from: https://doi.org/10.1111/j.1472-8206.2010.00901.x.
41. Chen CY, Tsao PN, Chen HL, Chou HC, Hsieh WS, Chang MH. Ursodeoxycholic acid (UDCA) therapy in
very-low birth-weight infants with parenteral nutrition-associated 1472-7859
42. Frongia G, Kessler M, Weih S, Nickkholgh A, Mehrabi A, Holland-Cunz S. Comparison of LILT and STEP
procedures in children with short bowel syndrome- a systematic review of the literature. J Pediatr Surg.
2013; 48:1794-805. Available from: https://doi.org/10.1016/j.jpedsurg.2013.05.018.
43. Bhat S, Cameron NR, Sharma P, Bissett IP, O'Grady G. Chyme recycling in the management of small bowel
double enterostomy in pediatric and neonatal populations: A systematic review. Clin Nutr ESPEN. 2020;
37:1-8. Available from: https://doi.org/10.1016/j.clnesp.2020.03.013.
44. Ghattaura H, Borooah M, Jester I. A review on safety and outcomes of mucous fistula refeeding in neonates.
Eur J Pediatr Surg. 2022; 32:146-52. Available from: https://doi.org/10.1055/s-0040-1718751.
45. Sparks EA, Khan FA, Fisher JG, Fullerton BS, Hall A, Raphael BP, et al. Necrotizing enterocolitis is
associated with earlier achievement of enteral autonomy in children with short bowel syndrome. J Pediatr
Surg. 2016; 51:92-5. Available from: https://doi.org/10.1016/j.jpedsurg.2015.10.023.
